Kornimate/medical-research-clean huggingface dataset:
assessment of the different etiological and susceptibility markers in patients with pancreatitis: investigating ig4, cytomegalovirus, coxsackie- virus, genetic polymorphism of vitamin d receptor gene

Conditions: Acute Pancreatitis

Summary: acute pancreatitis (ap) is a multifactorial disease. ap represents a significant number of hospital admissions. most of the patients are admitted in an acute setting. early identification of its etiology is an essential step toward the rational approach, both for its implications in the immediate therapy and the prevention of recurrence. although often obvious, the etiological workup of acute pancreatitis can be challenging.

acute pancreatitis is the most common pancreatic disorder. although acute pancreatitis is a benign disease, it often progresses to a serious state, and mortality is still high. autoimmune pancreatitis (aip) was first used to describe cases of pancreatitis with narrowing of the pancreatic duct, enlargement of the pancreas, hyper-γ-globulinaemia, and antinuclear antibody (ana) positivity serologically by indirect immunofluorescence (iif). the main differential diagnosis is pancreatic cancer, which can be ruled out through radiological, serological, and histological investigations. cytomegalovirus (cmv) is a common viral pathogen in humans. it is a lytic virus that causes a cytopathic effect in vitro and in vivo. seroprevalence for cmv worldwide ranges from 60%-100% but the severity of illness varies. primary cmv may be asymptomatic or may cause a mild and self-limiting mononucleosis-like syndrome. the self-limiting course of cmv infection typically includes fever, malaise, splenomegaly, mild hepatomegaly, small increases in serum transaminase activity, and variable elevation of serum alkaline phosphatase. cmv infection can cause severe hepatitis, meningitis, encephalitis, myelitis, colitis, pancreatitis and pneumonitis. coxsackie-b virus can also cause acute pancreatitis. vdr are also expressed on pancreatic ɓ cells, and may play an essential role in maintaining normal insulin levels in accordance to glucose concentrations and to maintain glucose tolerance. because vitamin d acts through vdr, their impairment or reduced functionality, e.g., as a result of polymorphisms occurring in the vdr gene, may have a crucial impact on the balance in the vitamin d concentration in the circulation, and the final metabolite activity throughout the body.

Eligibility criteria:
inclusion criteria: * patients with a confirmed diagnosis of acute pancreatitis. * patients of age 20 years or more who are willing to participate in the study and give their consent for same. exclusion criteria: * with a history of severe liver disease, * sepsis * chest disease.

Keywords: cytomegalovirus coxsackie- virus vitamin d receptor gene ig4 autoimmune pancreatitis
blind tracheal intubation through supraglottic airway devices

Conditions: Respiration and the Airways With Laryngeal Masks

Summary: tracheal intubation is considered the gold standard for protecting the airway. as the supraglottic airway devices (sads) could be inserted without laryngoscopy, so that sads with different designs and safety issues could be used to manage difficult airways in anesthesia and emergency medicine with continuous patient oxygenation \&ventilation, less hemodynamic stress response and less postoperative complications. these advantages encourage the use of a proper sad as a conduit for endotracheal intubation in stressful conditions. this study will be carried out to compare the air-qtm blocker and larysealtm pro for blind tracheal intubation during elective ophthalmic surgeries under general anesthesia. intubation through sad can be performed using a fiber-optic bronchoscope or blindly. blind intubation is meaning that the tube is inserted through sad without direct visualization of the airway. success rate of blind intubation ranges between 15% and 97%, mostly depending on the type of used sad, patient characteristics and operator skills. the availability of blind intubation through sad is important in cases of difficult intubation (either anticipated or unanticipated) especially if fiber-optic is not available, so that sad will be convenient for untrained personnel.

the laryseal pro could provide rapid and secure airway management and improve patient safety with gastric access reducing the risk of pulmonary aspiration, in addition to speeding up the ett tube placement with a unique guide system, beside to integrated fenestrated flap that protects from blockage with minimal increase in flow resistance, and elevates the epiglottis for easy, trauma-free ett tube or bronchoscope insertion. according to the manufacturer: all these features of laryseal pro allow quick easy first time insertion success. as, the laryseal pro is being of shorter breathing tube and smaller cuff in comparison to air-q blocker, so the laryseal pro is expecting to be more amazing than the air-q blocker especially for the new trainers regarding the total insertion time of the endotracheal tube and success rate. jatin et al. 2021reported that air-q intubating laryngeal airway resulted in significantly more success rate and ease of intubation as compared to ambu aura gain. andrzej et al. 2018 stated that success rate of blind intubation through air-q was 75% when compared to 80% in i-gel group. in contrary, there are limited studies available in literature on blind tracheal intubation through the laryseal pro.

Eligibility criteria:
inclusion criteria: 1. age: 18-55 years old. 2. asa i\&ii. 3. both sexes. 4. el-ganzouri airway score \< or =2 exclusion criteria: 1. history of upper respiratory tract infections. 2. history of obstructive sleep apnea (osa) or stop bang-score \> 4. 3. potentially full stomach (trauma, morbid obesity bmi\> 35 kg/m2, pregnancy, history of gastric regurgitation and heart burn). 4. esophageal reflux (hiatus hernia). 5. coagulation disorders.
feasibility study: compare the effectiveness between two pain medications when used prior to ultherapy™ treatments

Conditions: Skin Laxity

Summary: this study will compare the effectiveness of two pain medications for reducing discomfort during an ultherapy treatment.

this trial is a prospective, single-site, double-blinded, randomized trial. all study subjects will receive a full face and neck ultherapy treatment. subjects will be randomized to receive one of two pain medications prior to treatment. each subject will be asked to rate the level of discomfort during the ultherapy treatment. all study subjects will be followed for 90 days following treatment.

Eligibility criteria:
inclusion criteria: * male or female, aged 30 to 65 years * subject in good health * skin laxity on the upper and lower face and neck * understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the followup period exclusion criteria: * known sensitivity to ibuprofen, acetaminophen, or opiates * presence of an active systemic or local skin disease that may affect wound healing * severe solar elastosis * excessive subcutaneous fat in the face and neck * excessive skin laxity on the face and neck * significant scarring in areas to be treated * significant open facial wounds or lesions * severe or cystic acne on the face * presence of a metal stent or implant in the facial area to be treated
prevention of sequelae pain after breast cancer surgery by self-massages and self stretching. impact of learning workshops.

Conditions: Breast Cancer; Surgery

Summary: myofascial pain syndrome is a common cause of chronic pain characterized by myofascial pain and trigger points. recommendations regarding management of pain after breast cancer don't mention myofascial syndrome despite a study suggests possible myofascial syndrome with roughly 75% of patients in pain. 144 patients having a local breast cancer requiring surgery will be randomized in this study, ratio 1:1 standard and experimental groups. every patients (standard and experimental groups) will attend 4 specific consultations during which standard recommendations will be given, pain, quality of life, shoulder range of motion, global upper limbs force will be assessed. in addition, patient randomized in experimental group will attend self massages and self stretching workshops, one before surgery and one after surgery. patients will be encouraged to performed daily self massages and self stretching. the aim of the study is to assess impact of self massages and self stretching workshops on sequelae pain further surgery for breast cancer.


Eligibility criteria:
inclusion criteria: * woman * local development of breast cancer, every stages except stage iv * indication of surgery whatever surgery type except breast reconstruction * more than18 years * life expectancy \> 12 months assessed by surgeon or pain specialist * informed and written consent * affiliated to a social security system exclusion criteria: * history of chronic pain * history of shoulder pain * any illness or severe disease, medical or psychiatric, that could prevent the patient to follow study procedures or to give her informed consent, according investigators, * history of breast surgery * pregnant or lactating woman * protected adult or deprived of her liberty

Keywords: self massages and self stretching workshops for self massages and stretching learning
study to document treatment patterns and to evaluate leuprolide and alternative therapeutic approaches to the treatments of advanced prostate cancer

Conditions: Prostatic Neoplasm

Summary: document treatment patterns and evaluate lucrin / lucrin-tridepot® (leuprolide) and alternative therapeutic approaches to the treatment of advanced prostate cancer during normal clinical practice and in accordance with the terms of the belgian marketing authorization and reimbursement conditions.


Eligibility criteria:
inclusion criteria: * patients with advanced prostate cancer who have been prescribed lucrin/ lucrin-tri-depot or any other treatment with local reimbursement guidelines; patients willing to consent to data being collected and provided to abbott laboratories. exclusion criteria: * contraindications according to the summary of product characteristics (spc).

Keywords: multicenter study
a switch study from high-sodium oxybate to xywav to evaluate changes in blood pressure in participants with narcolepsy

Conditions: Narcolepsy

Summary: the aim of this study is to quantify the change in blood pressure when participants with narcolepsy treated with high-sodium oxybate are transitioned to xywav, a low-sodium oxybate. the results of this study may provide health care providers (hcps), patients, and payers with important new information regarding bp changes related to differences in sodium content between available oxybates for the treatment of narcolepsy.


Eligibility criteria:
key inclusion criteria: * participants must be 18 to 70 years of age inclusive, at the time of signing the informed consent. * participants have a documented diagnosis of type 1 or type 2 narcolepsy that meets international classification of sleep disorders (icsd)-3 or diagnostic and statistical manual of mental disorders (dsm)-5 criteria. * participants must have been receiving a total dose of high-sodium oxybate (eg, xyrem) of 6 to 9 g/night (inclusive) with twice-nightly dosing for a minimum of 6 consecutive weeks prior to screening. * if currently treated with stimulants and/or alerting agents or other medications known to affect bp, participant must have been taking the same dosing regimen for at least 2 months prior to screening and agree to take the same dose throughout the study. * if currently taking stable doses of antihypertensive therapies, participant must maintain these treatments at the same dose throughout the study unless otherwise advised by their medical care * participant is male or female. a female participant is eligible to participate if she is not pregnant or breastfeeding, if she is a woman of nonchildbearing potential or is a woman of childbearing potential and using a contraceptive method that is highly effective. key exclusion criteria: * history or presence of any acutely unstable medical condition, behavioral or psychiatric disorder (including active suicidal ideation), or surgical history that could affect the safety of the participant or interfere with study assessments or the ability of the participant to complete the study based on the judgment of the investigator. * presence of significant cardiovascular disease or cardiovascular condition that in the investigator's opinion may jeopardize participant safety in the study, including screening ecg results. * presence of atrial fibrillation detected on screening electrocardiogram (ecg). * presence of resistant hypertension.

Keywords: narcolepsy type 1 narcolepsy type 2 xywav jzp258 oxybate
efficacy of propolis varnish against oral biofilm

Conditions: Streptococcal Infections; Saliva Altered

Summary: this study aims to evaluate the effectiveness of a varnish containing 15% of green propolis on streptococcus mutans in saliva and biofilm. will be invited to join the study: children 8-10 years old, free of caries, without orthodontic appliances and without having undergone antibiotic therapy until three weeks before the start of the study. saliva will be collected before, immediately after, 24 hours and 30 days after application of the varnish. the collection of biofilm will be performed before, after, 24 hours and 30 days after application of the varnish. data will be collected and compared between periods.

antimicrobials are substances used in dentistry as an efficient way of caries prevention. substances such as chlorhexidine are the most known and most applied for this purpose and, as a varnish, increased its anticariogenic potential. the antimicrobial effects of natural substances are being studied for exhibiting antimicrobial properties similar to those of chlorhexidine, but less toxic in some cases. several studies with propolis has proven its efficacy against several microorganisms of the oral cavity, specially streptococcus mutans. a pharmaceutical formulation containing brazilian green propolis was developed based on the chitosan polymer that is biocompatible and biodegradable. in a previous study, we observed in vitro antimicrobial properties of the varnish against streptococcus mutans. this work aims to study the preliminary evidence of the efficacy of the propolis dental varnish in reducing streptococcus mutans in saliva and in the biofilm control through a phase ii study involving patients with 8-10 years. after 30 days, the results will be compared and statistically analyzed at a level of significance of 5 % .

Eligibility criteria:
inclusion criteria: * children 8-10 years old * good general health condition * not making use of mouthwashes or medications (especially antibiotics), until three weeks prior to the beginning of the experiment. exclusion criteria: * patients in medical treatment or who used drugs (especially antibiotics), in the three previous weeks and patients with active caries lesions.

Keywords: streptococcus mutans natural products
novel wireless mixed reality headset for image guidance in cardiac catheterization laboratory

Conditions: Radiation Injuries

Summary: our hypothesis is that improved line of sight to patient data, ergonomics, and headset lead shielding in the ccl will lead to behavioral changes in the ccl personnel that will reduce radiation exposure to all members of the team. further, reducing the burden of large, cumbersome monitors will enable improved use of shielding. our approach is a single center randomized controlled trial of consecutive patients randomly assigned to one of two groups with group 1 using mixed reality display and group 2 using standard 2d displays to perform diagnostic angiography in the ccl. radiation exposure will be evaluated at multiple levels including total radiation exposure, exposure of each individual staff member, as well as specific exposure to eyes and head in group 1 versus group 2.


Eligibility criteria:
inclusion criteria: * undergoing diagnostic coronary angiography exclusion criteria: * acute coronary syndrome, cardiogenic shock, cardiac arrest, planned intervention
study of duloxetine in elderly patients with major depressive disorder

Conditions: Depression; Cognition

Summary: a study of the safety and efficacy of duloxetine in elderly patients (greater than 65 years old) with major depressive disorder

duloxetine 60 mg qd and placebo variable-duration, placebo lead-in period 9 weeks in the acute treatment phase

Eligibility criteria:
inclusion criteria: * you must be able to visit the doctor's office for clinic visits, tests, and procedures. * you must have been diagnosed with major depression, and have had at least one other episode in the past. exclusion criteria: * you have a current or previous major psychiatric disorder other than depression, such as bipolar disorder, schizophrenia, or other psychotic disorder. * you have taken a drug within the last 30 days that has not been approved for use by governmental authorities.
determination of the in vitro effects of cationic airway lining modulators (calm) on chronic obstructive pulmonary disease (copd) sputum

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this study is intended to be an evaluation of the properties of human sputum collected from patients with copd. it is hypothesized that cationic airway lining modulators will have beneficial effects on the rheological properties of sputum derived from patients with copd. approximately 10 patients with copd will collect sputum at home for 5 days. samples will be collected and tested in laboratory tests.


Eligibility criteria:
inclusion criteria: 1. clinical and spirometric diagnosis of copd 2. smoking history of at least 10 pack yrs 3. sputum production of greater than 2 tablespoons per day by patient report. exclusion criteria: 1. a primary diagnosis of asthma or bronchiectasis 2. a copd exacerbation within 4 weeks 3. inability to comply with study procedures.

Keywords: sputum chronic obstructive pulmonary disease
study evaluating rgh-188 in the treatment of patients with schizophrenia

Conditions: Schizophrenia

Summary: this is a study designed to evalute the safety and efficacy of rgh-188 in the treatment of acute schizophrenia. this study will be 10 weeks in duration; 6 weeks double-blind treatment, and 4 weeks safety follow-up. all patients meeting the eligibility criteria will be randomized to one of the three treatment groups--one of two doses of rgh-188 or placebo


Eligibility criteria:
inclusion criteria: * male and female inpatients, 18-65 years of age, meeting dsm-iv-tr criteria for schizophrenia and having a total positive and negative syndrome scale (panss) score \>=80 and \ =4 on item p1 (delusions) or p3 (hallucinatory behavior) and a score of \>=4 on item p2 (conceptual disorganization) or p6 (suspiciousness/persecution) of the pnass exclusion criteria: * patients with documented disease of the central nervous system that can interfere with the trial assessments, including but not limited to stroke, tumor, parkinson's, organic brain disease, seizure disorder (except for febrile convulsions during infancy), chronic infection, or neurosyphilis; or patients who have suffered a traumatic brain injury resulting in significant impairment

Keywords: schizophrenia
an efficacy and safety study comparing oral contraceptive containing norgestimate or desogestrel for acne treatment

Conditions: Acne Vulgaris

Summary: the purpose of this study is to evaluate the efficacy and safety of ethinyl estradiol and norgestimate (ee/ngm) compared to ethinyl estradiol and desogestrel (ee/dsg), for treatment of female participants with mild to moderate acne vulgaris (pimples).

this is a single-blind (physician does not know the name of the assigned drug) and randomized (study drug assigned by chance) study to compare the effectiveness and safety of ee/ngm and ee/dsg in female participants using oral contraceptive and have mild to moderate acne vulgaris. tablets of ee/ngm and ee/dsg will be administered orally once daily for 6 months and will be instructed to visit for evaluation at month 1, 3 and 6 post-administration. the efficacy will be evaluated efficacy primarily through total acne lesions count, which will be recorded at these evaluation visits. unused study medications will be collected and drug accountability will be documented. participants' safety will be monitored throughout the study.

Eligibility criteria:
inclusion criteria: - needs contraception in the family planning - mild to moderate acne vulgaris - agrees to take only the supplied study drug as treatment for acne during the 6-month treatment phase of the study - signs and dates an informed consent to participate in the study - female participants aged 18 to 45 years exclusion criteria: - pregnant or nursing - known hypersensitivity to any of the ingredients and currently having significant adverse experiences from ethinyl estradiol, norgestimate or desogestrel - any coexisting medical condition or were taking any concomitant medication that is likely to interfere with safe administration of ethinyl estradiol/norgestimate and ethinyl estradiol/desogestrel, in the investigator's opinion - taking system retinoids, systemic antimicrobials, and topical acne treatments within 6 months, 1 month, and 2 weeks prior to enrollment, respectively - taking investigational medication or oral contraceptives within 30 days prior to screening

Keywords: acne vulgaris ethinyl estradiol norgestimate desogestrel tricilest oilezz
safety study of abatacept in rheumatoid arthritis participants

Conditions: Rheumatoid Arthritis

Summary: a observational study to assess whether biologic disease-modifying (bdm) treatment initiation with abatacept for rheumatoid arthritis is associated with an increased risk of serious infection and cancer


Eligibility criteria:
inclusion criteria: * patient initiates bdm treatment with at least one claim for the treatment. patients will be presumed to be new users of a treatment if there is no claim for the drug or any other bdm in the 180 days prior to the cohort entry date * patient has at least two diagnoses for ra in the patient's history prior to and including the entry date or within the 180 days after the entry date * patient is aged 18 years or older on the entry date * patient was enrolled in the database for at least 180 days before the entry date exclusion criteria: * patient is younger than 18 years on the entry date * patients who receive abatacept and another biologic simultaneously * patients who have an outcome diagnosis in the baseline period will be excluded from the cohort analyses for that outcome other protocol defined inclusion/exclusion criteria could apply